Navigation Links
Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
Date:9/21/2009

late stent thrombosis at three years was 0.3 percent** for XIENCE V and 1.0 percent for TAXUS (p-value=0.34). The ARC definitions of stent thrombosis were developed to eliminate variability in the definitions across various drug eluting stent trials.

Key Results from SPIRIT III

In the 1,002-patient SPIRIT III trial, XIENCE V demonstrated the following key results out to three years:

  • A 43 percent reduction in the risk of MACE compared to TAXUS (9.1 percent for XIENCE V vs. 15.7 percent for TAXUS, p-value=0.003).
  • A 43 percent reduction in the risk of Target Lesion Failure (TLF) compared to TAXUS (8.3 percent for XIENCE V vs. 14.4 percent for TAXUS, p-value=0.005). TLF is a composite measure of important efficacy and safety outcomes for patients, defined as cardiac death, target vessel MI and TLR.
  • A 30 percent reduction in the risk of Target Vessel Failure (TVF) compared to TAXUS (13.5 percent for XIENCE V vs. 19.2 percent for TAXUS, p-value=0.03). TVF is a composite clinical measure of safety and efficacy outcomes defined as cardiac death, MI or ischemia-driven target vessel revascularization (TVR).
  • A 42 percent reduction in the risk of heart attacks (MI) compared to TAXUS (3.7 percent for XIENCE V vs. 6.3 percent for TAXUS, p-value=0.07).
  • A 39 percent reduction in the risk of ID-TLR compared to TAXUS (5.4 percent for XIENCE V vs. 8.9 percent for TAXUS, p-value=0.05).
  • Per protocol definition, a 0.2 percent** rate of very late stent thrombosis compared to 1.0 percent for TAXUS (p-value=0.10). Per ARC definition of definite/probable stent thrombosis, the rate of very late stent thrombosis was 0.3 percent** for XIENCE V and 1.0 percent for TAXUS (p-value=0.34).

Consistent Results in SPIRIT III Subgroup Analyses

In addition to the positive three-year results for the overall study pres
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
2. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
3. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
4. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
5. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
6. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
7. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
10. Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing
11. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
(Date:7/10/2014)... 10, 2014  Breg, Inc., a premier provider ... the FreeRunner™ knee brace with new innovations to ... mal-tracking return to active lifestyles.  FreeRunner,s patent-pending design ... providing support when patients need it most, and ... Patellofemoral issues are the most common ...
(Date:7/10/2014)... Utah , July 10, 2014  BC Technical, ... and MiE America , Inc., a leading provider ... entered into a long-term agreement naming BC Technical as ... US. MiE and BC Technical announced ... agreement to establish BC Technical as the service and ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... Sept. 12, 2011 International Isotopes Inc (OTC Bulletin Board: ... an update of the Company,s general business status, particularly, the ... well as to discuss progress of its ongoing plans for ... Isotopes Inc General Business Update. When: ...
... Lewis County today launched a new program to help ... Through a partnership with the National Association of Counties (NACo), ... a card that offers an average of 24 percent savings ... The card can be used by those who do not ...
Cached Medicine Technology:International Isotopes Inc Announces Conference Call to Give an Update on the Company's General Business Status 2Lewis County Introduces Prescription Discount Card to Help Alleviate High Costs 2
(Date:7/14/2014)... 2014 According to the ... recently updated by Vkool.com, this is a ... range of simple and easy tips for ...     Increasing omega-3 fatty acids ... ,     Increasing fiber ,     Avoid ...
(Date:7/14/2014)... 14, 2014 Vaginal Mesh lawsuit ... seven different pelvic mesh manufacturers in the U.S. District ... Schulte LLC. The federal complaints are pending against pelvic ... American Medical Systems (MDL No. 2325), and C.R. Bard, ... are 58,262 Vaginal Mesh lawsuit claims pending, according to ...
(Date:7/14/2014)... July 14, 2014 Doctor Mike Hamilton ... launch of their new company website. The Inception website ... information on chiropractic marketing. It's also a place for ... has to offer. , When contacted at his office, ... version of our main website. Our site is obviously ...
(Date:7/14/2014)... Texas (PRWEB) July 14, 2014 ... forefront in complete spine care—from diagnosis to treatment and ... locations are either certified in or training for certification ... Theresa Adame, have recently completed the extensive program. , ... utilizing The McKenzie Method results in better outcomes for ...
(Date:7/14/2014)... Sacramento, CA (PRWEB) July 14, 2014 ... a new office in Sacramento. The announcement has been made ... the office. In addition, the announcement has been made in ... their dental services in the Sacramento area. , Crystal Dental ... procedures. Some of the services offered by Crystal Dental include ...
Breaking Medicine News(10 mins):Health News:Endometriosis Bible and Violet Protocol Book Review Exposes Zoe Brown's Endometriosis Treatment Guide – Vkool.com 2Health News:Endometriosis Bible and Violet Protocol Book Review Exposes Zoe Brown's Endometriosis Treatment Guide – Vkool.com 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 2Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 4Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 5Health News:Doctor Mike Hamilton From Inception Chiropractic Websites Announces the Launch of Their New Website 2Health News:Spine Team Texas’ Physical Therapists Complete The McKenzie Method Training and Certification 2Health News:Spine Team Texas’ Physical Therapists Complete The McKenzie Method Training and Certification 3Health News:Crystal Dental Announces the Opening of New Office Location in Sacramento 2
... May 29 The following is a,statement by Matthew ... World Health Organization,s World No Tobacco Day, to be ... toll of the global,tobacco epidemic and the urgent need ... and save lives., This year,s theme -- Tobacco-Free ...
... Area ... hospitals, PLANO, Texas, May ... in Chicago,Illinois, has extended its relationship with the global information,technology provider. Perot ... ago, and in that period of,time its team of revenue cycle professionals ...
... Alseres,Pharmaceuticals, Inc. (Nasdaq: ALSE ) today ... of Stockholders Thursday, June 12, 2008 at 1:00,p.m. ... Hale & Dorr, 60 State,Street, Boston, MA., ... Pharmaceuticals, Inc., Alseres Pharmaceuticals, Inc. (ALSE) is ...
... patients who suffer a heart attack never have any warning ... problem is noncalcified plaque, a buildup of soft deposits embedded ... angiography or cardiac stress tests and prone to rupture ... success in detecting and measuring noncalcified plaque. In a pilot ...
... University Massey Cancer Center researchers have identified that a ... chronic myelogenous leukemia cells previously resistant to conventional forms ... a cancer of the bone marrow caused by a ... common forms of leukemia. Imatinib mesylate, or Gleevec, is ...
... N.J., May 29 The Musculoskeletal Transplant,Foundation (MTF) ... needed for cartilage and joint repair for injured ... be given priority in obtaining,tissue used for cartilage ... in short supply, these types of tissue are ...
Cached Medicine News:Health News:World No Tobacco Day Sounds Urgent Call for Nations to Fight Tobacco Use, Save Lives 2Health News:World No Tobacco Day Sounds Urgent Call for Nations to Fight Tobacco Use, Save Lives 3Health News:Perot Systems and Sinai Health System Extend Revenue Cycle Solutions Contract 2Health News:Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting 2Health News:New method effective in detecting dangerous coronary plaque 2Health News:New method effective in detecting dangerous coronary plaque 3Health News:Combination of 2 novel anti-cancer agents may help fight CML resistant to current therapy 2
Full Handle Laseredge Spoon Blade Knife, 3.0 mm angled double bevel. Blade dimension: 11.0 mm (L) x 3.0 mm (W). Cut: 320....
Full Handle Laseredge Slit Blade Knife, 3.2 mm angled bevel up. Blade tip dimension: 14.4 mm x 3.2 mm x 3.7 mm....
Full Handle Laseredge Slit Blade Knife, 3.2 mm straight. Blade tip dimension: 14.4 mm x 3.2 mm x 3.7 mm....
Full Handle Laseredge Slit Blade Knife, 3.0 mm angled bevel up. Blade tip dimension: 14.4 mm x 3.0 mm x 3.7 mm....
Medicine Products: